Bank of New York Mellon Corp Has $29.14 Million Stock Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Bank of New York Mellon Corp lessened its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 3.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,468,609 shares of the biotechnology company’s stock after selling 52,557 shares during the period. Bank of New York Mellon Corp owned approximately 0.62% of ADMA Biologics worth $29,137,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ADMA. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics during the fourth quarter worth about $35,000. Tsfg LLC bought a new stake in ADMA Biologics during the first quarter worth about $51,000. Farther Finance Advisors LLC grew its stake in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock worth $53,000 after buying an additional 2,505 shares during the last quarter. AlphaQuest LLC bought a new stake in ADMA Biologics during the fourth quarter worth about $84,000. Finally, GF Fund Management CO. LTD. bought a new stake in ADMA Biologics during the fourth quarter worth about $85,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA opened at $17.69 on Thursday. The firm has a 50-day moving average of $19.36 and a 200-day moving average of $18.76. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67. The company has a market cap of $4.22 billion, a PE ratio of 20.81 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business’s quarterly revenue was up 40.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 EPS. As a group, equities analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares in the company, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company’s stock, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock valued at $9,644,269 over the last ninety days. 3.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ADMA shares. Wall Street Zen cut shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Raymond James Financial raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.